Integer Holdings Co. (NYSE:ITGR) VP Tommy P. Thomas Sells 1,500 Shares

Integer Holdings Co. (NYSE:ITGR) VP Tommy P. Thomas sold 1,500 shares of the firm’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $114.00, for a total value of $171,000.00. Following the completion of the transaction, the vice president now directly owns 2,813 shares in the company, valued at approximately $320,682. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Integer Trading Up 0.1 %

ITGR opened at $109.92 on Friday. Integer Holdings Co. has a 52 week low of $69.40 and a 52 week high of $123.99. The business has a fifty day simple moving average of $114.06 and a 200-day simple moving average of $100.73. The firm has a market cap of $3.68 billion, a P/E ratio of 38.03, a P/E/G ratio of 1.62 and a beta of 1.12. The company has a quick ratio of 2.01, a current ratio of 3.32 and a debt-to-equity ratio of 0.76.

Integer (NYSE:ITGR) last released its earnings results on Thursday, April 25th. The medical equipment provider reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.12 by $0.02. The firm had revenue of $414.80 million during the quarter, compared to analyst estimates of $412.78 million. Integer had a return on equity of 11.25% and a net margin of 6.01%. Integer’s revenue was up 9.5% compared to the same quarter last year. During the same period last year, the business posted $0.87 earnings per share. On average, equities analysts expect that Integer Holdings Co. will post 5.27 earnings per share for the current year.

Institutional Trading of Integer

Several institutional investors and hedge funds have recently made changes to their positions in ITGR. Raymond James & Associates raised its stake in Integer by 4.0% during the 3rd quarter. Raymond James & Associates now owns 40,700 shares of the medical equipment provider’s stock valued at $3,192,000 after acquiring an additional 1,564 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Integer by 16.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,902 shares of the medical equipment provider’s stock worth $384,000 after acquiring an additional 684 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Integer by 2.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 16,489 shares of the medical equipment provider’s stock worth $1,293,000 after acquiring an additional 353 shares during the period. Park Avenue Securities LLC purchased a new stake in Integer in the 3rd quarter valued at approximately $462,000. Finally, Emerald Advisers LLC lifted its stake in Integer by 6.4% in the 3rd quarter. Emerald Advisers LLC now owns 18,883 shares of the medical equipment provider’s stock valued at $1,481,000 after buying an additional 1,138 shares in the last quarter. 99.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently issued reports on ITGR shares. Benchmark reissued a “buy” rating and set a $130.00 target price on shares of Integer in a research note on Friday, April 26th. KeyCorp lifted their target price on Integer from $123.00 to $139.00 and gave the stock an “overweight” rating in a report on Tuesday, April 9th. CL King assumed coverage on Integer in a report on Thursday, March 14th. They issued a “buy” rating and a $137.00 target price for the company. Finally, Bank of America upgraded Integer from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $105.00 to $135.00 in a report on Monday, April 15th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Integer has a consensus rating of “Moderate Buy” and a consensus target price of $120.50.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.